Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests

Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests

Mar 12, 2020
|
staff reporter

NEW YORK – Natera said after the close of the market on Thursday that on March 8, it terminated its license, development, and distribution agreement with Qiagen to develop and distribute next-gen sequencing-based genetic tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Vaccine Supply Chain Hacker Warning

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

Illinois Cuts Forensic Testing Backlog

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

Lying Plea

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

Science Studies on Nonalcoholic Fatty Liver Disease Expression Signatures, Ties Between Gut Microbiome and Major Depression

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.

What's Popular?

In Business News

  1. Ravgen Sues Illumina, Roche Alleging Infringement of Cell-Free DNA Testing Patents

  2. Proteomics Firm Seer Prices $175M IPO

  3. Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

  4. Swedish Sequencing Firm Single Technologies Raises $6.1M

  5. Aetna Updates Noninvasive Prenatal Testing Coverage Policy to Include All Pregnancies

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.